Rhythm Pharmaceuticals, Inc. · NASDAQ:RYTM

Rhythm Pharmaceuticals — European Society for Paediatric Endocrinology 2022

5 slides from Rhythm Pharmaceuticals's conference presentation, Sep 15, 2022

  1. Slide 1: Effects of Setmelanotide Treatment in Children and Adolescents With POMC, LEPR Deficiency and BBS

    Effects of Setmelanotide Treatment in Children and Adolescents With Proopiomelanocortin (POMC) Deficiency, Leptin Receptor (LEPR) Deficiency, and Bardet-Biedl Syndrome (BBS) RFC4.2 Session Date: Rapid Free Communications 4. Thursday 15 September 2022. Session Time: 14:25-14:55. Presentation time: 14

  2. Slide 2: Disclosure Statement

    DISCLOSURE STATEMENT Jesús Argente X I have the following potential conflicts of interest to report:   Research Contracts  Consulting  Employment in the Industry  Stockholder of a healthcare company  Owner of a healthcare company X Other(s) – Advisory board for Rhythm Pharmaceuticals, Inc.  N

  3. Slide 3: Variants in POMC, PCSK1, LEPR, and BBS Genes Are Associated With Hyperphagia and Early-Onset, Severe Obesity

    Variants in POMC, PCSK1, LEPR, and BBS Genes Are Associated With Hyperphagia and Early-Onset, Severe Obesity1-6 • Early intervention is critical for reducing disease burden, but consensus on optimally assessing the effects of antiobesity medications in pediatric patients is lacking7 • The MC4R agoni

  4. Slide 4: Setmelanotide Was Associated With Reductions in All Weight-Related Measures in Pediatric Patients

    Setmelanotide Was Associated With Reductions in All Weight-Related Measures in Pediatric Patients With POMC Deficiency, LEPR Deficiency, and BBS BMI BMI Z Score %BMI95 POMC (n=8) LEPR (n=4) BBS (n=14) POMC (n=8) LEPR (n=4) BBS (n=14) POMC (n=8) LEPR (n=4) BBS (n=14) 0 0 0 Mean change in BMI Z score

  5. Slide 5: Summary and Conclusions

    Summary and Conclusions • Setmelanotide was associated with improvements across all weight-related measures in pediatric patients with POMC (including PCSK1) deficiency, LEPR deficiency, and BBS • The variability observed across weight parameters and populations highlights a need to identify optimal

Rhythm Pharmaceuticals — European Society for Paediatric Endocrinology 2022 on 6ix